Skip to content
Back to Blog
Bio
2026-11-017 min read14

50 Pharma-Bio SMEs a Year, Up to 5 Years of Support — How to Prepare for the 'K-Pharma-Bio Frontier Company' Program Announced on October 29 by the Ministry of Health and Welfare and the Ministry of SMEs and Startups (200 Companies by 2030)

This guide covers the K-Pharma-Bio Frontier Company plan announced by Korea's health and SME ministries on October 29: selection numbers for the three fields, the 2+3-year support structure, and a checklist of milestones and funding links to prepare before the call opens.

KITIM Consulting Team

What Was Announced on October 29

At the National Policy Coordination Meeting on October 29, the Ministry of Health and Welfare and the Ministry of SMEs and Startups jointly announced the "K-Pharma-Bio Frontier Company" development plan. The two ministries will jointly select 50 companies a year, for a total of 200 by 2030. At a September 17 industry meeting the plan was described as "in preparation." It is now final.

The government's targets for 2030 are 500 new pharma-bio SME startups and $5.5 billion in exports. The earlier "Pharma-Bio Venture Full-Cycle Collaboration Plan" (4UP / growth ladder) focused on linking each ministry's programs from one stage to the next. The new plan is different: it combines the policy tools of both ministries into a single selection and support track.

Three Fields and How Many Companies Each

Reported annual selection numbers:

  • New drug development: 20 companies
  • Medical devices and digital health: 20 companies
  • Bio-materials and manufacturing technology: 10 companies
  • The bio-materials and manufacturing field is open to CDMOs and companies that supply bio materials, parts and equipment. Three questions can help you decide which field to apply in:

  • Core pipeline: Does most of your value come from therapeutics, devices, or materials and processes?
  • Revenue model: Do you earn mainly from licensing deals, or from product sales and contract manufacturing?
  • Regulatory stage: Are you in clinical trials, close to approval or certification, or already on the market?
  • Support Structure: Two Years, Then Three More

  • Phase 1 (2 years): Each company is paired one-on-one with a growth director. Together they build a tailored growth strategy, and the company receives R&D, clinical and commercialization support
  • Phase 2 (3 years): Companies with strong results get three more years of support, including investment links and help expanding overseas
  • Reports disagree on the funding figures. Some describe "KRW 60 billion in investment plus KRW 90 billion in commercialization guarantees over three years." Others give only a total of KRW 150 billion. Check the government's official briefing and the detailed call for applications for exact numbers.

    The government has said follow-on evaluations will not be based only on revenue or licensing deals. This means companies with long development timelines can still get credit for interim progress. So design clear milestones from the start, such as completing preclinical work, filing an IND or obtaining a certification. These milestones will largely decide whether you reach Phase 2.

    Joint Steering Committee and Designation Revocation

    A joint steering committee run by both ministries will decide the support fields, the evaluation criteria, which companies are selected, and when a designation is revoked. Because revocation is written into the plan, selected companies will need a system for tracking and reporting their performance.

    The detailed call for applications has not yet been published. It will cover eligibility, the application schedule and how the growth directors will work. Keep watching the websites of both ministries, K-Startup and the Korea Health Industry Development Institute (KHIDI).

    New R&D Running Alongside: Animal-Alternative Testing and AI Healthcare

  • Animal-alternative testing: R&D on technologies such as organoids and organ-on-a-chip, in response to the US FDA's move to reduce animal testing
  • Advanced AI healthcare: a new R&D program for AI in healthcare
  • Companies can compete for these new projects separately from Frontier selection. They are worth a look for organoid and organ-on-chip platform companies, preclinical CROs and medical AI software developers.

    What to Prepare Before the Call Opens

  • Map the development stage of each pipeline asset or product and set five-year milestones. Include performance indicators other than licensing
  • Review your past government projects and check whether any duplicate-funding restrictions apply
  • Gather your investment history, IR materials and options for using guarantees
  • Define your clinical and regulatory roadmap and your target overseas markets
  • Some critics say the funding is small compared with what drug development costs. Plan in advance how to combine it with other R&D programs and policy funds
  • How KITIM Can Help

    KITIM helps pharma-bio companies prepare for Frontier selection. We advise on choosing a field, writing the growth strategy and designing five-year milestones. We also build funding portfolios that link government R&D with clinical support programs. If you want to start preparing before the detailed call is released, please contact KITIM through our inquiry page to book a consultation.

    K-Pharma-Bio Frontier CompanyMOHW MSS Joint SupportBio SMEPharma-Bio R&DGrowth DirectorBio Investment and GuaranteeMedical Device Digital Health

    Related Posts

    Bio

    Biologics Approval Fees Rise From KRW 8.03M to 20.71M, Data-Submission Drugs About 6x — MFDS Fee Regulation Amendment Pre-Announced Nov 6, 2026 (Comments Due Nov 26 / Dec 16): Filing Timing, Budget Review and Fee-Reduction Checks for Pharma & Bio SMEs

    Under the fee amendment MFDS proposed on November 6, approval fees for new biologics would rise from KRW 8.03 million to KRW 20.71 million, and fees for data-submission drugs would go up about sixfold. This guide shows pharma and bio SMEs how to review their filing timing, budgets, fee-reduction eligibility and public comments.

    2026-11-09
    Management Consulting

    Factories With 20–49 Workers Will Need a Safety or Health Manager — Korea's First Tripartite Agreement on November 5 (About 30,000 Sites in 5 Industries Including Manufacturing, Decree Amendment in 2027, Target Start 2028), the Owner-Led Alternative and Government Payroll Support: A Preparation Guide for Small Manufacturers

    Under Korea's November 5 tripartite agreement, about 30,000 sites with 20–49 workers in manufacturing and four other industries are expected to need a qualified safety or health manager from 2028. This guide covers what is settled and what is still open, the owner-led alternative, a cost comparison, and a preparation checklist.

    2026-11-09
    ESG

    A Green Certification Is Just Paper Unless You Use It — A 2026 Guide for Climate-Tech SMEs on Choosing Between Green Technology Certification, Green Product Confirmation and Green Specialized Company Confirmation, and Using Them for Procurement, Guarantees and R&D, Amid the Revised Operating Rules and Criticism of Unverified Reduction Effects

    This guide covers the revised green certification rules and recent criticism over unverified emissions reductions. It also explains how climate-tech SMEs can choose among the three green certifications and use them for procurement, guarantees and R&D.

    2026-11-09
    Updated daily

    Let AI find government support programs in this field

    Complete a 3-minute company assessment and we will recommend programs that fit your company, each with a match score. It is free.

    Get AI-Matched Programs for Free

    Need Consulting?

    Our technology innovation consultants will propose the optimal solution for your company.